Abstract
The two currently available HIV integrase inhibitors — raltegravir and elvitegravir — share similar resistance profiles, such that resistance to one drug generally confers resistance to the other. However, the investigational, next-generation integrase inhibitor dolutegravir seems to have a distinct resistance profile, retaining significant antiviral activity in patients who have failed raltegravir-based therapy. In a study supported by the manufacturer of dolutegravir, a …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
